Man-made Chemicals Causing Hormone Disruption

by | Mar 2, 2013

GENEVA, Feb 19, 2013 (Reuters) – Man-made chemicals in everyday products are likely to be at least the partial cause of a global surge in birth deformities, hormonal cancers, and psychiatric diseases, a U.N.-sponsored research team reported on Tuesday.

These substances, dubbed Endocrine Disrupting Chemicals (EDCs), could also be linked to a decline in the human male sperm count and female fertility, PMS, Endometriosis, Uterine Fibroids, hot flashes and an increase in breast, uterine and ovarian cancers.

I’ve written and spoken out about this subject frequently over the past 5 years.  If you have wondered why it seems like you and everyone you know is having significant hormone issues this is the reason why. Watch this video to learn what you can do about it.

https://www.youtube.com/watch?v=y_hvB2R4AVE

The international group, academic experts working under the umbrella of the United Nations environmental and health agencies UNEP and WHO, issued their recent findings in a paper updating a 2002 study on the potential dangers of synthetic chemicals. Declaring “a global threat that needs to be resolved,” the team said humans and animals across the planet were probably exposed to hundreds of these often little-studied or understood compounds at any one time.

“We live in a world in which man-made chemicals have become part of everyday life,” said their 28-page report, “State of the Science of Endocrine Disrupting Chemicals, 2012,” issued as a policy guide for governments. EDCs include phthalates long used in making plastics soft and flexible. Products made from them include toys, children’s dummies, perfumes and pharmaceuticals, as well as cosmetics like deodorants that are absorbed into the body.

Another is Bisphenol A, or BPA, which is used to harden plastics and is found in food and beverage containers, including some babies’ bottles and the coating of food cans.

Dr. Hansen recommends that all women past puberty should have their hormones tested regularly to look for imbalances, especially if they have any symptoms of PMS, irregular cycles, infertility, Endometriosis, Uterine Fibroids, Ovarian cysts, Fibro Cystic Breast Disease, hot flashes, etc. These are all warning signs of hormonal imbalances that can be corrected by the correct prescription of Bio-Identical Hormones.

If you’re not feeling like yourself these days, consider having your hormones tested. We can help you get back to feeling like your old self again!


Schedule an Appiontment

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

8 + 11 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });